RecruitingNot applicableNCT07318051
Official study title

Sample Collection for Ongoing Research and Product Evaluation Study

Study summary

The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera's molecular residual disease (MRD) testing across multiple cancer types. The study aims to assess the ability of Natera's assays to detect circulating tumor DNA (ctDNA) as a marker for disease recurrence and treatment response.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forRecurrent or relapsed

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 15, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Natera, Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Natera, Inc.
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1. 18 years of age or older. 2. Any patient that has an untreated primary solid malignancy within the following cohorts: 1. Breast cancer 2. Lung cancer 3. Muscle invasive bladder cancer 4. Rectal cancer 5. Pancreatic cancer 6. Ovarian cancer 7. Gastroesophageal cancer 8. Prostate cancer 9. Melanoma 10. Hepatic/liver cancer 11. Uterine/endometrial cancer 12. Head and neck Cancer 3. The participant has a suspected primary malignancy of pancreatic, endometrial, bladder, or ovarian cancer based on imaging. 4. Eastern Cooperative Oncology Group performance status ≤ 2. 5. Able to tolerate venipuncture for research blood draw(s). 6. Consent to provide residual tumor tissue for research. 7. Willing and able to comply with the study requirements. 8. Signed informed consent(s) must be obtained prior to participation in the study.

Reasons someone may not be able to joinExclusion criteria

1. Pregnant or breastfeeding. 2. Prior history and treatment for any cancer within the past year or has another active cancer, with the exception of participants who have undergone surgical removal of skin squamous cell or basal cell cancers. 3. Has initiated postoperative systemic treatment. 4. At time of enrollment, has undergone or plans to undergo any ctDNA testing to assess molecular residual disease, with the exception of comprehensive genomic profiling for therapeutic selection. 5. History of bone marrow or organ transplant. 6. Serious medical conditions that may adversely affect ability to participate in the study.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Natera, Inc.Austin, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 15, 2026. Always confirm current availability with the study team.

View original record ↗